状況選択肢を比べるとき
Wanting augmentation without an implant
どのような状況か
Some people want a larger or fuller breast but do not want a foreign body, a visible edge, or the maintenance that implants can involve. They look for the alternative that uses their own tissue and weigh it against implants on the size increase it can realistically give, how long it lasts, what the safety record says, and what it costs over time. This is a comparison situation, so the honest answer includes the limits of fat grafting as well as its advantages.
よくある不安: fear of foreign body · natural feel · size expectation
この状況で比べる条件
各条件はエンティティページの事実で答えます。[n] は出典へ続きます。
Achievable size increase
- Typical size increase
- Surgeon quoted by ASPS: ideal candidate wants half a cup to one cup; a larger increase may take two to three procedures[4]organizationFat transfer for breast augmentation: The ins and outs of this implant alternativeAmerican Society of Plastic Surgeons
- Suitable for
- People wanting a relatively small increase in breast size who have enough donor fat (ASPS)[1]organizationFat Transfer Breast AugmentationAmerican Society of Plastic Surgeons
Long-term retention
- Pooled volume retention
- 54% (95% CI 48.5–59.5%) across 25 studies, follow-up 3–36 months[5]journalVolume retention rate after breast autogenous fat grafting and related influencing factors: A systematic review and meta-analysis (Hu S, Xu H; PMID 38160589; DOI 10.1016/j.bjps.2023.12.003) – abstract recordJournal of Plastic, Reconstructive & Aesthetic Surgery (via Europe PMC)
Safety and oncologic evidence
- Listed risks
- Cysts, infection, microcalcification, death of fat cells (necrosis), and some transferred fat leaving the breast area[3]organizationFat Transfer Breast Augmentation Risks and SafetyAmerican Society of Plastic Surgeons
- Oncologic safety evidence
- Meta-analysis of 15 studies (8,541 participants): no difference in overall survival, disease-free survival or local recurrence between patients who had fat grafting after breast cancer surgery and controls[6]journalThe oncological safety of autologous fat grafting: a systematic review and meta-analysis (Goncalves R et al.; BMC Cancer; PMCID PMC9004160) – abstract recordBMC Cancer (via Europe PMC)
What implants involve
- Known risksBreast Implant
- Rupture, capsular contracture, need for imaging adaptations, possible replacement[2]governmentBreast enlargement (implants)NHS (UK National Health Service)
関連する質問
한 번에 300cc 이상 넣는 대용량 가슴 지방이식은 가능한가요? 조건과 위험은 무엇인가요?가능하지만 조건이 붙습니다. 외부 확장기(Brava)를 4주간 착용한 뒤 가슴당 평균 277~346 mL 를 넣은 연구들에서 12개월 생착률 82%, 6개월 이후 순증 266 mL 가 보고됐지만, 모두 같은 저자 그룹의 근거 수준 IV 연구입니다. 독립 연구에서는 100cc 이상 대용량 이식 뒤 지방괴사(멍울)가 32.9%였고, 한쪽 450cc 를 넘기면 괴사가 더 늘었습니다. 충분한 공여 …지방이식 vs 보형물, 어떤 차이가 있나요?보형물은 인공 기기를 넣는 방식이어서 구형구축, 파열, 정기 영상검사가 관리 대상입니다. 지방이식은 본인의 지방을 옮기는 방식으로, 기름 낭종과 지방 괴사가 대표적인 합병증입니다. 반복 시술이 필요할 수도 있습니다. 2026년 무작위 대조시험 메타분석의 한 비교에서는 중대한 합병증이 지방이식 1.2%, 보형물 10.5%였습니다. 다만 대상이 주로 재건 환자였고 추적 기간이 짧았습니다.
医療機関の確認方法
順位ではなく、この種の施術について韓国に存在する公的記録を使ってください。
- 保健福祉部の先端再生医療実施機関の指定一覧で指定番号を確認します。
- 細胞を分離・処理する施術なら、細胞処理施設の許可状況(K-ARM)を確認します。
- 機関自身が公表する症例数・成功率・「初」の表現は、独立した記録が確認するまで公式主張として扱います。
参考文献
- レベル C · organizationFat Transfer Breast Augmentation — American Society of Plastic Surgeons · 根拠ページ
- レベル A · governmentBreast enlargement (implants) — NHS (UK National Health Service) · 根拠ページ
- レベル C · organizationFat Transfer Breast Augmentation Risks and Safety — American Society of Plastic Surgeons · 根拠ページ
- レベル C · organizationFat transfer for breast augmentation: The ins and outs of this implant alternative — American Society of Plastic Surgeons · 根拠ページ
- レベル B · journalVolume retention rate after breast autogenous fat grafting and related influencing factors: A systematic review and meta-analysis (Hu S, Xu H; PMID 38160589; DOI 10.1016/j.bjps.2023.12.003) – abstract record — Journal of Plastic, Reconstructive & Aesthetic Surgery (via Europe PMC) · 根拠ページ
- レベル B · journalThe oncological safety of autologous fat grafting: a systematic review and meta-analysis (Goncalves R et al.; BMC Cancer; PMCID PMC9004160) – abstract record — BMC Cancer (via Europe PMC) · 根拠ページ